CD40-related receptor that binds CD40L

File for Quick & Easy Patent Protection with PowerPatent.

The Incyte Corporation patent solves the following problem:

Signal transduction is the general process that cells respond to extracellular signals. Signal transduction across the plasma membrane began to bind a signal molecule, for example, a hormone, neurotransmitter, or growth factors, into a cell membrane receptor. receptor, thus activated, triggers an intracellular biochemical cascade that ends with the activation of an intracellular target molecule, such as a transcription factors. This process of signal transduction regulates all kinds of cell functions, including cell growth, inequality, and gene transcription.

Our analysis of this patent is as follows:

Incyte Corporation’s patent US 7378492 B2 deals with CD40-related receptor that binds CD40L.
Various embodiments of the invention provide human receptor-associated membrane protein (REMAP) and Q polynucleotides which identify and encode REMAP. Embodiments of the invention also giving expression vector, host cells, antibodies, agonists and antagonists. Some embodiments provide methods for diagnosing, treating, or preventing diseases associated with aberrant expression of REMAP.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Human phospholipases

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Incyte Corporation patent solves the following problem:

Lipid water-insoluble, oily or greasy substances that dissolve in nonpolar solvents such as chloroform or ether used. Neutral fat (triacylglycerols) to serve as the major fuel and energy stores. Polar lipid, such as phospholipids, sphingolipids, glycolipids, and cholesterol, the key structural components of cell membranes. (Lipid Metabolism review Stryer, L. (1995) Biochemistry, WH Freeman and Company, New York NY; Lehninger, A. (1982) Principles of Biochemistry, Worth Publishers, Inc. New York NY, and biochemical ExPASy track index Boehringer Mannheim online publication.)

Our analysis of this patent is as follows:

Incyte Corporation’s patent US 7368270 B2 deals with Human phospholipases.
human invention provides lipid metabolism enzyme (LME) and polynucleotides which identify and encode LME. invention also provides expression vector, host cells, antibodies, agonists and antagonists. invention also provides methods for diagnosing, treating, or preventing diseases associated with aberrant expression of LME.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.